Zurzuvae PPD denied as not medically necessary by Aetna?

Aetna's specific coverage criteria for zurzuvae ppd are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Zurzuvae (Zuranolone) for PPD on Medical-Necessity Grounds

Aetna's medical-necessity denials for Zurzuvae in postpartum depression (PPD) typically occur when the clinical record does not clearly document that the patient meets the criteria outlined in Aetna's published coverage policy for this agent. Because Zurzuvae is a newer FDA-approved oral neuroactive steroid, Aetna reviewers apply close scrutiny to diagnosis confirmation, prior-treatment history, and the severity of the current episode.

## Why This Denial Is Appealable

Zurzuvae received FDA approval specifically for major depressive disorder (MDD) in adults, with postpartum depression representing a key indicated population. A denial that contradicts the FDA-approved labeling or your insurer's own published coverage criteria is a reviewable adverse benefit determination under both ACA §2719 and ERISA §503. If the plan is self-funded, ERISA's full-and-fair review standard applies; if it is fully insured, your state insurance department's external-review rules apply in addition.

## Federal Appeal Framework

• Internal appeal: Submit within the timeframe stated in your denial letter (typically 180 days for ERISA plans). The plan must respond within 60 days for pre-service and 60 days for post-service appeals.
• External review (ACA §2719 / ERISA §503): After exhausting internal appeals, you have up to 4 months (approximately 120 days from the final internal denial) to request independent external review by an accredited IRO.
• Expedited option: If delay would seriously jeopardize your health, request expedited internal and external review simultaneously — decisions are required within 72 hours.

## Documentation to Gather

1. Diagnosis confirmation: DSM-5 documented diagnosis of MDD with peripartum onset (PPD) from the treating clinician, including onset timing relative to delivery. 2. Clinical severity: Office notes, validated depression-severity scale scores recorded in the chart, and any documentation of functional impairment or safety concerns. 3. Prior-treatment history: Names of previously tried antidepressants, dates started and stopped, and documented reasons for discontinuation (lack of efficacy, intolerability, or clinical contraindication per the prescriber). 4. Medical-necessity letter: A detailed letter from the prescribing clinician or psychiatrist explaining why Zurzuvae is medically necessary for this patient at this time, referencing the FDA-approved indication and the applicable clinical guideline organization (e.g., the relevant psychiatric or obstetric professional society guideline). 5. Insurer policy alignment: Obtain Aetna's current published Clinical Policy Bulletin for Zurzuvae. Copy each stated requirement into your appeal and map the exact chart documentation that satisfies it.

## Criteria-Mapping Structure

In your appeal letter, use a table or numbered list formatted as:

• Policy requirement (verbatim from Aetna's bulletin): [paste exact language]
• How this patient meets it: [cite specific chart note, date, and clinician name]

Address every listed criterion individually. Reviewers are required to evaluate each documented response; unanswered criteria are the most common reason appeals fail on the first round. Attach all supporting records as labeled exhibits referenced in the letter body.